Neurovive Pharmaceutical AB, of Stockholm, said enrollment in its ongoing phase IIa study with Neurostat for treating patients with severe traumatic brain injury (TBI) is continuing, and another two patients have been enrolled, bringing the number to seven out of a total 20 patients that are targeted.